Xencor Financial Statements
NASDAQ: XNCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xencor revenue and earnings
In fiscal 2025, Xencor generated $125.6 million in revenue, up 13.7% from fiscal 2024. Xencor reported a net loss of $91.9 million, compared with a loss of $232.6 million a year earlier. Operating margin was -141.4%.
Diluted earnings per share came in at -$1.24. Over the last 5 fiscal years, XNCR's revenue has grown at a 0.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Xencor income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.58M | 110.49M | 174.62M | 164.58M | 275.11M | 122.69M | 156.70M | 40.60M | 46.15M | 109.02M |
| Revenue growth (YoY) | +13.65% | -36.72% | +6.10% | -40.18% | +124.23% | -21.70% | +285.93% | -12.02% | -57.67% | — |
| Operating Expenses | 303.08M | 288.90M | 306.98M | 247.05M | 231.34M | 199.49M | 142.88M | 119.97M | 89.27M | 64.98M |
| Research & Development | 239.43M | 227.69M | 253.60M | 199.56M | 192.51M | 169.80M | 118.59M | 97.50M | 71.77M | 51.87M |
| Operating Income | -177.50M | -178.41M | -132.36M | -82.47M | 43.77M | -76.80M | 13.82M | -79.37M | -43.12M | 44.04M |
| Interest Expense | 31.93M | 36.64M | 6.18M | 13.00K | 13.00K | — | — | 16.00K | 13.00K | 21.00K |
| Other Income (Expense) | 87.87M | -56.52M | 12.73M | 27.96M | 38.86M | 7.46M | 13.36M | 8.96M | 4.17M | 2.08M |
| Pretax Income | -89.63M | -234.92M | -119.63M | -54.51M | 82.63M | -69.33M | 27.19M | -70.41M | -38.95M | 46.12M |
| Income Tax | 2.50M | 1.62M | 13.66M | 673.00K | 0 | 0 | 312.00K | 0 | -463.00K | 991.00K |
| Net Income | -91.92M | -232.62M | -133.13M | -55.18M | 82.63M | -69.33M | 26.88M | -70.41M | -38.49M | 45.13M |
| Net Income growth (YoY) | — | — | — | -166.78% | — | -357.98% | — | — | -185.29% | — |
| EPS (Basic) | -1.24 | -3.58 | -2.20 | -0.93 | 1.42 | -1.21 | 0.48 | -1.31 | -0.82 | 1.09 |
| EPS (Diluted) | -1.24 | -3.58 | -2.20 | -0.93 | 1.37 | -1.21 | 0.46 | -1.31 | -0.82 | 1.07 |
| Shares Outstanding (Basic) | 74.24M | 65.04M | 60.50M | 59.65M | 58.38M | 57.21M | 56.53M | 53.94M | 46.82M | 41.27M |
| Shares Outstanding (Diluted) | 74.24M | 65.04M | 60.50M | 59.65M | 60.50M | 57.21M | 58.47M | 53.94M | 46.82M | 42.39M |
| EBITDA | -166.99M | -166.30M | -120.86M | -73.67M | 51.26M | -71.00M | 18.12M | -76.12M | -41.09M | 45.51M |
| Operating Margin | -141.35% | -161.47% | -75.80% | -50.11% | 15.91% | -62.59% | 8.82% | -195.48% | -93.44% | 40.40% |
| Net Margin | -73.20% | -210.53% | -76.24% | -33.53% | 30.04% | -56.51% | 17.15% | -173.41% | -83.39% | 41.39% |
This table shows 10 annual periods of Xencor's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow XNCR's reporting calendar. What is a income statement?